Construction and Assessment of a Novel Vaccine Targeting Hepatocellular Carcinoma
Hessin, A., Hegazy, R., Safar, M., Yassin, N., Kenawy, S. (2020). Construction and Assessment of a Novel Vaccine Targeting Hepatocellular Carcinoma. EKB Journal Management System, 63(3), 867-884. doi: 10.21608/ejchem.2019.14690.1894
Alyaa Hessin; Rehab Hegazy; Marwa Safar; Nemat Yassin; Sanaa Kenawy. "Construction and Assessment of a Novel Vaccine Targeting Hepatocellular Carcinoma". EKB Journal Management System, 63, 3, 2020, 867-884. doi: 10.21608/ejchem.2019.14690.1894
Hessin, A., Hegazy, R., Safar, M., Yassin, N., Kenawy, S. (2020). 'Construction and Assessment of a Novel Vaccine Targeting Hepatocellular Carcinoma', EKB Journal Management System, 63(3), pp. 867-884. doi: 10.21608/ejchem.2019.14690.1894
Hessin, A., Hegazy, R., Safar, M., Yassin, N., Kenawy, S. Construction and Assessment of a Novel Vaccine Targeting Hepatocellular Carcinoma. EKB Journal Management System, 2020; 63(3): 867-884. doi: 10.21608/ejchem.2019.14690.1894

Construction and Assessment of a Novel Vaccine Targeting Hepatocellular Carcinoma

Egyptian Journal of Chemistry
Article 75, Volume 63, Issue 3, March 2020, Page 867-884  XML PDF (2.15 MB)
Document Type: Original Article
DOI: 10.21608/ejchem.2019.14690.1894
View on SCiNiTO View on SCiNiTO
Authors
Alyaa Hessin email orcid 1, 2; Rehab Hegazy3; Marwa Safar4; Nemat Yassinorcid 3; Sanaa Kenawy5
1Department of Pharmacology, Division of Medical, National Research Centre, Giza, Egypt
2Department of Microbiology and Immunology, College of Medicine, UIC, IL, USA.
3Department of Pharmacology, Division of Medical, National Research Centre, Giza, Egypt.
43Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Giza, Egypt
5Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Giza, Egypt.
Abstract
IMMUNOTHERAPY is a promising and highly effective method of targeting hepatocellular carcinoma (HCC) cells and improving patient outcomes. There is a continuing need for the development and refinement of current vaccine vehicles to safely target tumors while stimulating robust cell-mediated immune responses. The facultative intracellular bacterium Listeria monocytogenes has proven to be an effective vehicle for the design of cancer vaccines that stimulate potent and long CD8+ T-cell responses. Critical facets of its effectiveness relate to the ability of gaining access to the cytosol of infected host cells and delivering tumor-associated antigens. Here we describe the development and testing of L. monocytogenes ΔprsA2 ΔhtrA strains as effective vaccine vehicles for the safe delivery of HCC antigens. Recombinant L. monocytogenes ΔprsA2 ΔhtrA was engineered to express α-fetoprotein antigens designed to elicit immunity against HCC cells, and tested in a subcutaneous mouse model together with the previously developed L. monocytogenes ΔactA prfA* strain. The results suggest that L. monocytogenes ΔprsA2 ΔhtrA strains may represent a highly attenuated yet effective vaccine vector capable of stimulating immunity against HCC cells in vivo.
Keywords
Hepatocellular carcinoma; Immunotherapy; Listeria monocytogenes; Tumors; Vaccine vectors
Statistics
Article View: 507
PDF Download: 296